Pidotimod, an
immunostimulant, is researched for over two decades. Current evidence indicates its utility in a variety of indications in children as well as in adults. Its
immunostimulant activity has been firmly established in the management of recurrent
respiratory infections in children with or without
asthma. Compared to standard of care alone, addition of
pidotimod to standard of care significantly prevents the recurrences and reduces the severity and duration of acute episodes, ultimately resulting in reduced visits to pediatric clinics and lower absenteeism at school. In adults,
pidotimod is effective in the prevention and treatment of acute infectious exacerbations of
chronic bronchitis and
chronic obstructive pulmonary disease (
COPD). Further, it has been evaluated in indications such as
pneumonia, hand-food-
mouth disease,
bronchiectasis, and
chronic idiopathic urticaria. From a total of 32 studies conducted in child (24 studies) and adult (8 studies) population, this in-depth review discusses the current evidence of
pidotimod. With further exploration, the
immunostimulant activity of
pidotimod might be extended to different immunological disorders.